Oruka Therapeutics (ORKA) SVP exercises options, sells shares to cover tax obligations
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Oruka Therapeutics, Inc. Senior Vice President, Finance Arjun Agarwal reported a mix of option exercises and related share sales in company common stock. On June 12, 2026, he exercised employee stock options for 8,000 shares at $12.50 per share and 1,459 shares at $34.39 per share, increasing his direct holdings.
On the same day and on June 15, 2026, he sold an aggregate of 9,854 shares of common stock in multiple open-market transactions at weighted average prices ranging from about the high $60s to around $70 per share. According to the footnotes, these sales were carried out under Oruka’s automatic, non-discretionary sell-to-cover procedure to satisfy tax withholding obligations tied to vesting of restricted stock units and were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026.
Following these transactions, Agarwal directly holds 16,899 shares of Oruka Therapeutics common stock. The filing also notes that his holdings include 888 shares acquired through the company’s stock purchase plan on June 8, 2026.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 9,854 shares ($687,035)
Net Sell
8 txns
Insider
Agarwal Arjun
Role
Senior Vice President, Finance
Sold
9,854 shs ($687K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 395 | $69.69 | $28K |
| Exercise | Employee Stock Option (right to buy) | 8,000 | $0.00 | -- |
| Exercise | Employee Stock Option (right to buy) | 1,459 | $0.00 | -- |
| Exercise | Common Stock | 8,000 | $12.50 | $100K |
| Exercise | Common Stock | 1,459 | $34.39 | $50K |
| Sale | Common Stock | 1,859 | $68.3419 | $127K |
| Sale | Common Stock | 4,340 | $69.8512 | $303K |
| Sale | Common Stock | 3,260 | $70.3392 | $229K |
Holdings After Transaction:
Common Stock — 16,899 shares (Direct, null);
Employee Stock Option (right to buy) — 110,000 shares (Direct, null)
Footnotes (1)
- Includes 888 shares acquired under the Oruka Therapeutics, Inc. stock purchase plan on June 8, 2026. These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.87 to $68.71, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3), (4) and (5) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.07 to $70.06, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.07 to $70.86, inclusive. The reported sales were effected pursuant to Oruka Therapeutics, Inc.'s automatic, non-discretionary, sell-to-cover procedure to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units. The option vests as to 1/48 of the underlying shares monthly from January 1, 2025. The option vests as to 1/48 of the underlying shares monthly from January 1, 2026.
Key Figures
Shares sold 06/15/2026: 395 shares at $69.69
Shares sold 06/12/2026 block 1: 3,260 shares at $70.3392
Shares sold 06/12/2026 block 2: 4,340 shares at $69.8512
+5 more
8 metrics
Shares sold 06/15/2026
395 shares at $69.69
Open-market sale of common stock on June 15, 2026
Shares sold 06/12/2026 block 1
3,260 shares at $70.3392
Open-market sale of common stock on June 12, 2026
Shares sold 06/12/2026 block 2
4,340 shares at $69.8512
Open-market sale of common stock on June 12, 2026
Shares sold 06/12/2026 block 3
1,859 shares at $68.3419
Open-market sale of common stock on June 12, 2026
Options exercised 1
8,000 shares at $12.50
Employee stock option exercise into common stock on June 12, 2026
Options exercised 2
1,459 shares at $34.39
Employee stock option exercise into common stock on June 12, 2026
Total shares sold
9,854 shares
Aggregate common shares sold across reported S-code transactions
Shares held after transactions
16,899 shares
Direct common stock holdings following June 15, 2026 sale
Key Terms
Rule 10b5-1 trading plan, sell-to-cover procedure, restricted stock units, weighted average price, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
sell-to-cover procedure financial
"The reported sales were effected pursuant to Oruka Therapeutics, Inc.'s automatic, non-discretionary, sell-to-cover procedure to satisfy tax withholding obligations..."
restricted stock units financial
"sell-to-cover procedure to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
weighted average price financial
"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions..."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
stock purchase plan financial
"Includes 888 shares acquired under the Oruka Therapeutics, Inc. stock purchase plan on June 8, 2026."
A stock purchase plan is a company-run program that lets employees or qualifying investors buy the company’s shares regularly, often through paycheck deductions and sometimes at a discounted price or with matching contributions. It matters because it encourages ownership—like a workplace discount for buying company products—aligning interests between holders and managers, while affecting share supply and potential value for outside investors.
FAQ
What transactions did Oruka Therapeutics (ORKA) executive Arjun Agarwal report?
Arjun Agarwal reported exercising stock options and related share sales. He exercised options for 9,459 common shares, then sold 9,854 shares in multiple transactions, primarily to cover tax obligations from restricted stock unit vesting under automatic procedures.
What stock options did Arjun Agarwal exercise in Oruka Therapeutics (ORKA)?
He exercised employee stock options covering 8,000 shares at $12.50 per share and 1,459 shares at $34.39 per share. These exercises converted derivative positions into common stock, preceding the tax-related share sales described in the same Form 4.
What is the significance of the Rule 10b5-1 trading plan mentioned for ORKA?
The filing notes that the sales were effected under a Rule 10b5-1 trading plan. Such plans pre-schedule trades when the insider is not aware of material nonpublic information, making the timing more routine and reducing interpretation of the trades as opportunistic.